ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3‐ITD

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3‐ITD

Bromodomain‐containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/β‐catenin pathway. Meanwhile, homoharringtoni...

Full description

Bibliographic Details
Main Authors: Yu Qian, Xiang Zhang, Shihui Mao, Wenwen Wei, Xiangjie Lin, Qing Ling, Wenle Ye, Fenglin Li, Jiajia Pan, Yutong Zhou, Yanchun Zhao, Xin Huang, Jiansong Huang, Hongyan Tong, Jie Sun, Jie Jin
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Molecular Oncology
Subjects:
acute myeloid leukemia
FLT3‐ITD
homoharringtonine
novel BRD4 Inhibitor ACC010
Online Access:https://doi.org/10.1002/1878-0261.13368

Internet

https://doi.org/10.1002/1878-0261.13368

Similar Items